After months of debate, the U.S. Food and Drug Administration (FDA) has announced stricter controls on the diabetes drug troglitazone (Rezulin), saying doctors should use it only for patients who don't respond to other therapies and only in conjunction with other diabetes drugs such as insulin. The FDA's move comes after an advisory committee investigated a link between the drug and about 40 cases of liver failure, including 28 deaths. Under new regulations, doctors will be required to monitor all troglitazone patients monthly for the first year and every three months thereafter for potential liver damage. So, be careful!
0 comments:
Post a Comment